Analgesic Drugs and COVID-19

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Anesthesiology".

Deadline for manuscript submissions: closed (31 December 2021) | Viewed by 14493

Special Issue Editor

Special Issue Information

Dear Colleagues,

Pain represents a terrible burden for a large part of humanity. Health care professionals are frequently requested to cope with patients in pain, both acute and chronic. The obvious approach is the prescription of analgesic medicines. These drugs are also very diffused as OTC, and frequently patients use them besides the prescribed ones, with little or no control.

The COVID-19 pandemic has posed many problems, including difficulties visiting and monitoring patients that are in pain. It is very difficult to clearly understand what is going on with them, and how they manage their pain conditions. Besides that, there have been warnings of potential interactions between analgesics and COVID-19.

This Special Issue of Journal of Clinical Medicine would contribute to make clear the relationship between the use of analgesic drugs and COVID-19, or more in general with infectious diseases. In particular, it would collect clinical experiences and scientific data related to the potential actions of analgesics in patients already affected by COVID-19. Additionally, it would be important and interesting to see if there are good and clear data connecting the use of analgesics (especially Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)) and the incidence of COVID or other infectious diseases.

Dr. Giustino Varrassi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • analgesic drugs
  • NSAIDs
  • opioids
  • adjuvant analgesics
  • COVID-19
  • infectious diseases

Published Papers (4 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Editorial

Jump to: Review, Other

2 pages, 177 KiB  
Editorial
Analgesic Drugs and COVID-19
by Giustino Varrassi
J. Clin. Med. 2021, 10(3), 545; https://doi.org/10.3390/jcm10030545 - 2 Feb 2021
Viewed by 2209
Abstract
COVID-19 pandemic represents a big challenge for the health care systems [...] Full article
(This article belongs to the Special Issue Analgesic Drugs and COVID-19)

Review

Jump to: Editorial, Other

8 pages, 984 KiB  
Review
How to Manage Withdrawal of Sedation and Analgesia in Mechanically Ventilated COVID-19 Patients?
by Amédée Ego, Katarina Halenarova, Jacques Creteur and Fabio Silvio Taccone
J. Clin. Med. 2021, 10(21), 4917; https://doi.org/10.3390/jcm10214917 - 24 Oct 2021
Cited by 9 | Viewed by 6978
Abstract
COVID-19 patients suffering from severe acute respiratory distress syndrome (ARDS) require mechanical ventilation (MV) for respiratory failure. To achieve these ventilatory goals, it has been observed that COVID-19 patients in particular require high regimens and prolonged use of sedatives, analgesics and neuromuscular blocking [...] Read more.
COVID-19 patients suffering from severe acute respiratory distress syndrome (ARDS) require mechanical ventilation (MV) for respiratory failure. To achieve these ventilatory goals, it has been observed that COVID-19 patients in particular require high regimens and prolonged use of sedatives, analgesics and neuromuscular blocking agents (NMBA). Withdrawal from analgo-sedation may induce a “drug withdrawal syndrome” (DWS), i.e., clinical symptoms of anxiety, tremor, agitation, hallucinations and vomiting, as a result of adrenergic activation and hyperalgesia. We describe the epidemiology, mechanisms leading to this syndrome and our strategies to prevent and treat it. Full article
(This article belongs to the Special Issue Analgesic Drugs and COVID-19)
Show Figures

Figure 1

14 pages, 255 KiB  
Review
Practical Advices for Treating Chronic Pain in the Time of COVID-19: A Narrative Review Focusing on Interventional Techniques
by Giuliano Lo Bianco, Alfonso Papa, Michael E. Schatman, Andrea Tinnirello, Gaetano Terranova, Matteo Luigi Giuseppe Leoni, Hannah Shapiro and Sebastiano Mercadante
J. Clin. Med. 2021, 10(11), 2303; https://doi.org/10.3390/jcm10112303 - 25 May 2021
Cited by 6 | Viewed by 2676
Abstract
Background: Since the management of chronic pain has become even more challenging secondary to the occurrence of SARS-CoV-2 outbreaks, we developed an exhaustive narrative review of the scientific literature, providing practical advices regarding the management of chronic pain in patients with suspected, presumed, [...] Read more.
Background: Since the management of chronic pain has become even more challenging secondary to the occurrence of SARS-CoV-2 outbreaks, we developed an exhaustive narrative review of the scientific literature, providing practical advices regarding the management of chronic pain in patients with suspected, presumed, or confirmed SARS-CoV-2 infection. We focused particularly on interventional procedures, where physicians are in closer contact with patients. Methods: Narrative Review of the most relevant articles published between June and December of 2020 that focused on the treatment of chronic pain in COVID-19 patients. Results: Careful triage of patients is mandatory in order to avoid overcrowding of hospital spaces. Telemedicine could represent a promising tool to replace in-person visits and as a screening tool prior to admitting patients to hospitals. Opioid medications can affect the immune response, and therefore, care should be taken prior to initiating new treatments and increasing dosages. Epidural steroids should be avoided or limited to the lowest effective dose. Non urgent interventional procedures such as spinal cord stimulation and intrathecal pumps should be postponed. The use of personal protective equipment and disinfectants represent an important component of the strategy to prevent viral spread to operators and cross-infection between patients due to the SARS-CoV-2 outbreaks. Full article
(This article belongs to the Special Issue Analgesic Drugs and COVID-19)

Other

Jump to: Editorial, Review

2 pages, 228 KiB  
Comment
Avoiding, Not Managing, Drug Withdrawal Syndrome in the Setting of COVID-19 Acute Respiratory Distress Syndrome. Comment on Ego et al. How to Manage Withdrawal of Sedation and Analgesia in Mechanically Ventilated COVID-19 Patients? J. Clin. Med. 2021, 10, 4917
by Fabrice Petitjeans, Marc de Kock, Marco Ghignone and Luc Quintin
J. Clin. Med. 2022, 11(12), 3336; https://doi.org/10.3390/jcm11123336 - 10 Jun 2022
Cited by 1 | Viewed by 1037
Abstract
The management of sedation in the setting of COVID-19 (“COVID”) by Ego et al. [...] Full article
(This article belongs to the Special Issue Analgesic Drugs and COVID-19)
Back to TopTop